Lv4
610 积分 2023-05-15 加入
Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions
1个月前
已完结
Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology
1个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
2个月前
已完结
Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy
2个月前
已完结
Stoichiometric Antibody–Polymer–Drug Conjugate for Effective Low-Dose Treatment of Breast Cancer
2个月前
已完结
Analytical tools for antibody–drug conjugates: From in vitro to in vivo
3个月前
已完结
Antibody-drug conjugates: Principles and opportunities
4个月前
已完结
Exploring the next generation of antibody–drug conjugates
4个月前
已完结
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
4个月前
已完结
皖公网安备34019202002308
